Sciformix Awarded Pharmaceutical KPO Entrepreneurial Company of the Year
News Jul 18, 2013
Sciformix Corporation has announced that it has received Frost & Sullivan’s prestigious Pharmaceutical Knowledge Process Outsourcing (KPO) Entrepreneurial Company of the Year award.
Based on its recent analysis of the pharmaceutical sourcing market, Frost & Sullivan recognizes Sciformix for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic service development.
Each year, Frost & Sullivan presents this award to the company that has demonstrated entrepreneurial spirit by devising a strong growth strategy and robustly implementing it.
Sciformix has shown strength in terms of innovation in business processes, leadership in customer value as well as market penetration.
The award looks at the emerging market players in the industry and recognizes their best practices that are positioned for future growth excellence.
Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best-practice organizations.
The award recognizes Sciformix as a unique, scientific, knowledge-based company among KPO organizations with regard to its depth and breadth of Life Science expertise in supporting its clients through the entire drug development cycle to provide a broad range of services, from study design to post-marketing surveillance and commercialization support.
Its unique client-centric and flexible business model spans client needs from niche requests to end-to-end support, and its global talent pool of PhDs, doctors, pharmacists, statisticians, programmers, medical writers, regulatory affairs and TA experts afford Sciformix the ability to adapt to the constantly changing healthcare and life sciences environment.
The award was benchmarked against strict criteria, which saw Sciformix outperforming its competitors. These include growth strategy excellence, growth implementation excellence, degree of innovation with products and technologies, leadership in customer value and speed of response to market needs.
One of the reasons Sciformix was awarded this honor was because of its ability to fill the gaps left by Business Process Organizations (BPOs) and Contract Research Organizations (CROs) who may focus more on operations and less on science, or more on science and not as much on processes, or larger multi- industry organizations that lack the advantage of specialized Life Science expertise.
Sciformix is also recognized because it has attracted an extensive pool of talent with diverse capabilities and abundant subject-matter expertise in all phases of drug development, from initiation of clinical trials to post-marketing support, and its ability to tailor flexible solutions to help clients quickly, efficiently and safely bring drugs to the market and manage the product lifecycle after approval.
“It is a great achievement for Sciformix to receive this prestigious award and be recognized for our entrepreneurship and commitment to innovation. We are investing in our people to encourage our talented employees to consistently develop and apply innovative ideas and approaches,” said Ajit Nagral, executive chairman of Sciformix Corporation.
In addition, “Our client-focused and flexible business model ensures that we provide expertise in both science and operations to our clients, delivering the best possible outcomes for patients and manufacturers in regard to safety and efficacy of drugs.”
Sciformix’s mission is to partner with global Life Science companies to provide high-quality, scientific, knowledge-based expertise that delivers better quality outcomes and improved efficiencies across the entire product lifecycle with the ultimate objective of improving quality of healthcare for patients worldwide.
Areas of specialization include Safety and Risk Management, Clinical Research and Post-Approval Service Support, Medical Affairs, Scientific Writing and Regulatory Affairs.